PARI Pharma GmbH Revenue and Competitors
Estimated Revenue & Valuation
- PARI Pharma GmbH's estimated annual revenue is currently $15.6M per year.
- PARI Pharma GmbH's estimated revenue per employee is $251,000
Employee Data
- PARI Pharma GmbH has 62 Employees.
- PARI Pharma GmbH grew their employee count by -9% last year.
PARI Pharma GmbH's People
Name | Title | Email/Phone |
---|
PARI Pharma GmbH Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $5M | 40 | -18% | $10M | N/A |
#2 | $24.8M | 99 | 29% | N/A | N/A |
#3 | $84.1M | 0 | N/A | $1.2M | N/A |
#4 | $35.6M | 142 | 30% | N/A | N/A |
#5 | $57.5M | 229 | 6% | N/A | N/A |
#6 | $52.7M | 168 | 25% | $129.6M | N/A |
#7 | $21.1M | 84 | -3% | N/A | N/A |
#8 | $61.2M | 244 | -13% | N/A | N/A |
#9 | $60.6M | 193 | 20% | $115.5M | N/A |
#10 | $56.2M | 179 | -3% | $122.9M | N/A |
What Is PARI Pharma GmbH?
PARI Pharma GmbH is a medical devices company based out of STEINERSTRASSE 15A, Munich, Germany.
keywords:N/AN/A
Total Funding
62
Number of Employees
$15.6M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
PARI Pharma GmbH News
2022-04-17 - Savara Announces Debt Refinancing of $26.5M Credit Facility ...
Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience...
2022-03-30 - Savara Reports Fourth Quarter / Year-End 2021 Financial ...
Molgramostim is delivered via an investigational eFlow® Nebulizer System (PARI Pharma GmbH). Our management team has significant experience...
2022-03-22 - Insmed to Showcase New Data Across Three Pillars at the American Thoracic
Society 2022 International Conference
ARIKAYCE is administered once daily using the Lamira® Nebulizer System manufactured by PARI Pharma GmbH (PARI). About PARI Pharma and the...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $14.4M | 63 | 6200% | N/A |
#2 | $11.4M | 63 | 2% | N/A |
#3 | N/A | 63 | 2% | N/A |
#4 | $18.4M | 63 | 7% | N/A |
#5 | $9.8M | 63 | 40% | N/A |